Voss Funds disclose 699,440 and 316,768 shares in RNTX

Rhea-AI Filing Summary

Voss-affiliated investors reported initial beneficial ownership in Rein Therapeutics, Inc. (RNTX). The Form 3, covering an event dated 09/24/2025 and filed on 10/03/2025, shows the filing group collectively beneficially owns over 10% of Rein Therapeutics common stock. The filing lists Voss Value Master Fund, LP with 699,440 shares and Voss Value-Oriented Special Situations Fund, LP with 316,768 shares, held indirectly through Voss Advisors GP, LLC, Voss Capital, LP and Travis W. Cocke. The report is a joint Form 3 by multiple Voss entities and Mr. Cocke and disclaims ownership beyond pecuniary interest.

Positive

• Group reported collective beneficial ownership of over 10%
• Voss Value Master Fund directly holds 699,440 shares
• Voss Value-Oriented Special Situations Fund directly holds 316,768 shares
• Form 3 filed jointly and signed by Travis W. Cocke on 10/03/2025

Negative

• None.

Insights

Governance & Ownership Analyst

Voss group disclosed a >10% passive ownership stake in RNTX, signaling an influential shareholder presence.

What it means: The filing identifies a group of affiliated entities and an individual—Voss Value Master Fund, LP, Voss Value-Oriented Special Situations Fund, LP, Voss Advisors GP, LLC, Voss Capital, LP, and Travis W. Cocke—that together beneficially own over 10% of Rein Therapeutics.

Why it matters: Crossing the 10% threshold is a regulatory disclosure trigger and signals a shareholder with potential voting influence or interest in engagement. The Form 3 shows specific share counts of 699,440 and 316,768 held by two funds, which establishes the factual baseline for the groups stake without indicating any additional actions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Voss Capital, LP

(Last) (First) (Middle)

3773 RICHMOND AVENUE, SUITE 850

(Street)

HOUSTON TX 77046

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2025

3. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.001 par value(1)	699,440	I	By: Voss Value Master Fund, LP(2)
Common Stock, $0.001 par value(1)	316,768	I	By: Voss Value-Oriented Special Situations Fund, LP(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Voss Capital, LP

(Last) (First) (Middle)

3773 RICHMOND AVENUE, SUITE 850

(Street)

HOUSTON TX 77046

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Voss Value Master Fund, LP

(Last) (First) (Middle)

3773 RICHMOND AVENUE, SUITE 850

(Street)

HOUSTON TX 77046

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Voss Value-Oriented Special Situations Fund, LP

(Last) (First) (Middle)

3773 RICHMOND AVENUE, SUITE 850

(Street)

HOUSTON TX 77046

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Voss Advisors GP, LLC

(Last) (First) (Middle)

3773 RICHMOND AVENUE, SUITE 850

(Street)

HOUSTON TX 77046

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Cocke Travis W.

(Last) (First) (Middle)

3773 RICHMOND AVENUE, SUITE 850

(Street)

HOUSTON TX 77046

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This Form 3 is filed jointly by Voss Value Master Fund, LP ("Voss Value Master Fund"), Voss Value-Oriented Special Situations Fund, LP ("Voss Value-Oriented Special Situations Fund"), Voss Advisors GP, LLC ("Voss GP"), Voss Capital, LP ("Voss Capital") and Travis W. Cocke (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

2. Securities owned directly by Voss Value Master Fund. Voss GP, as the general partner of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Voss Capital, as the investment manager of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund.

3. Securities owned directly by Voss Value-Oriented Special Situations Fund. Voss GP, as the general partner of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Voss Capital, as the investment manager of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund.

	Voss Capital, LP; By: /s/ Travis W. Cocke, Managing Member	10/03/2025
	Voss Value Master Fund, LP; By: Voss Advisors GP, LLC; By: /s/ Travis W. Cocke, Managing Member	10/03/2025
	Voss Value-Oriented Special Situations Fund, LP; By: Voss Advisors GP, LLC; By: /s/ Travis W. Cocke, Managing Member	10/03/2025
	Voss Advisors GP, LLC; By: /s/ Travis W. Cocke, Managing Member	10/03/2025
	/s/ Travis W. Cocke	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Voss group disclose in the Form 3 for Rein Therapeutics (RNTX)?

The Form 3 disclosed that affiliated Voss entities and Travis W. Cocke collectively beneficially own over 10% of Rein Therapeutics common stock.

How many shares does Voss Value Master Fund own in RNTX?

The filing reports that Voss Value Master Fund, LP directly owns 699,440 shares of Rein Therapeutics common stock.

How many shares does Voss Value-Oriented Special Situations Fund own in RNTX?

The filing reports that Voss Value-Oriented Special Situations Fund, LP directly owns 316,768 shares of Rein Therapeutics common stock.

When was the event date and filing date reported on the Form 3?

The event requiring the statement is dated 09/24/2025 and the Form 3 was signed and filed on 10/03/2025.

Who signed the Form 3 for the Voss reporting group?

The Form 3 was signed by /s/ Travis W. Cocke as Managing Member for the Voss entities on 10/03/2025.